Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to be appointed to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, faced serious malfunctions after its launch in Canada, including under-infusion and over-infusion of medications [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the Canadian rollout would help resolve any issues [5]. Group 3: Stock Impact - Following the announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, Baxter's stock price dropped by $6.29, or over 22%, from $28.05 to $21.76 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][2]. Allegations - The complaint alleges that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple malfunctions, injuries, and deaths related to the Novum LVP but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVP were claimed to be materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, that Baxter would suspend all new Novum LVP sales, the company's stock price dropped by 22.4%, closing at $21.76 [3]. Next Steps for Shareholders - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by December 15, 2025 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Company Background - Robbins LLP, the firm handling the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].

LOS ANGELES--(BUSINESS WIRE)--Baxter International Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – BAX. ...

Core Points - A class action lawsuit has been filed against Baxter International Inc. for alleged violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit claims that Baxter made false and misleading statements regarding its supply chain issues, which were concealed from investors [4] - Investors who purchased Baxter's securities between May 25, 2022, and February 8, 2023, are encouraged to participate in the lawsuit [2] Company Information - Baxter is accused of misleading investors about its ability to maintain a strong supply chain amidst global challenges [4] - The company's projected earnings were deemed misleading, leading to investor damages once the truth was revealed [4] Legal Context - The class action lawsuit is being represented by the Schall Law Firm, which specializes in securities class action lawsuits and shareholder rights litigation [5] - Investors are advised to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3]

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths associated with these defects but failed to adequately address the issues through customer alerts [3]. - The company's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Impact on Stock and Legal Proceedings - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price dropped by 22.4%, closing at $21.76 [4]. - Investors who suffered losses between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for alleged violations of federal securities laws related to the Novum LVP device malfunctions, which posed serious risks to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Baxter securities between February 23, 2023, and July 30, 2025 [2]. - Allegations include that Baxter misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Baxter have until December 15, 2025, to request to be appointed as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, due to alleged misleading information regarding the safety and efficacy of the Novum LVP product line [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which led to malfunctions that posed serious risks to patients, including underinfusion, overinfusion, and non-delivery of fluids [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [5]. - The lawsuit alleges that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Class Action Participation - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of Baxter International Inc. shareholders who purchased stock between February 23, 2022, and July 30, 2025, alleging that the company misled investors regarding the safety and efficacy of its Novum LVP devices [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP devices, which led to malfunctions and posed serious risks to patients [5]. - Allegations include that Baxter was aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [5]. - The lawsuit asserts that Baxter's statements about the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Participation Information - Shareholders who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6].

Core Viewpoint - Baxter International, Inc. is facing a securities fraud class action lawsuit due to safety concerns and misleading information regarding its Novum IQ Large Volume Pump, which has been linked to serious patient injuries and deaths [3][4]. Summary by Sections Incident Overview - Safety concerns regarding Baxter's Novum IQ Large Volume Pump emerged on April 7, 2025, following a whistleblower report about inaccurate infusion [3]. - Baxter issued a warning letter on April 24, 2025, acknowledging potential underinfusion risks and disclosing one serious injury [3]. - A second warning letter was sent on July 14, 2025, revealing 79 reports of serious injuries and two patient deaths related to the device [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a share price decline of $6.29, or approximately 22.4%, from $28.05 to $21.76 [3]. Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter securities from February 23, 2022, to July 30, 2025 [4]. - Allegations include failure to disclose systemic defects in the Novum LVP, which caused malfunctions and exposed patients to serious risks [4]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [4]. - The lawsuit claims that there was a heightened risk of customers removing existing Novum LVPs from service and a complete pause in new sales [4].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [2][3]. Allegations - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were allegedly materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, regarding the suspension of all new Novum LVP sales, Baxter's stock price dropped by 22.4%, closing at $21.76 [3]. Class Action Participation - Shareholders interested in participating in the class action must submit their papers by December 15, 2025, to serve as lead plaintiff [4].